Trumenba
Author: Karolina Kujawa
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Trumenba (Pfizer) is a bivalent recombinant meningococcal serogroup B vaccine indicated for immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in individuals aged 10−25 years in the US. Trumenba is a sterile suspension composed of two recombinant lapidated factor H binding protein variants. Factor H binding protein is found on the surface of meningococci and enhances the bacterium’s ability to avoid host defense.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Trumenba : Meningococcal vaccines
LIST OF TABLES
6 Table 1: Trumenba drug profile
7 Table 2: Approval history of Trumenba for meningococcal vaccination in the US and five major EU markets
8 Table 3: Late-phase trials of Trumenba for meningococcal vaccination
9 Table 4: Trumenba for meningococcal disease – SWOT analysis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
MenQuadfi 
Sign up to the